Objectives
It is not known whether current use of the medication primidone affects brain gamma-aminobutyric acid (GABA) concentrations. This is an important potential confound in studies of the pathophysiology of essential tremor (ET), one of the most common neurological diseases. We compared GABA concentrations in the dentate nucleus in 6 ET patients taking primidone vs. 26 ET patients not taking primidone.
Methods
1H magnetic resonance spectroscopy (MRS) was performed using a 3.0 Tesla Siemens Tim Trio scanner. The MEGA-PRESS J-editing sequence was used for GABA detection in two cerebellar volumes of interest (left and right) that included the dentate nucleus.
Results
The right dentate GABA concentration was similar in the two groups (2.21 ± 0.46 [on primidone] vs. 1.93 ± 0.39 [not on primidone], p=0.15), as was the left dentate GABA concentration (1.61 ± 0.35 [on primidone] vs. 1.67 ± 0.34 [not on primidone], p=0.72). The daily primidone dose was not associated with either right or left dentate GABA concentrations (respective p = 0.89 and 0.76).
Conclusions
We did not find a difference in dentate GABA concentrations between 6 ET cases taking daily primidone and 26 ET cases not taking primidone. Furthermore, there was no association between daily primidone dose and dentate GABA concentration. These data suggest that it is not necessary to exclude ET patients on primidone from MRS studies of dentate GABA concentration and, if assessment of these concentrations were to be developed as a biomarker for ET, primidone usage would not confound interpretation of the results.